Sutro Biopharma, Inc.

Healthcare · Biotechnology · United States

Last price 9.1 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 150.89M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcin...